טוען...
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs....
שמור ב:
Main Authors: | , , , , , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Adis, Springer Healthcare
2019-05-01
|
סדרה: | Rheumatology and Therapy |
נושאים: | |
גישה מקוונת: | http://link.springer.com/article/10.1007/s40744-019-0157-3 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|